Safety Evaluation of Recombinant Fusion Protein RP22 as a Skin Test Reagent for Tuberculosis Diagnosis: A Phase I Clinical Trial

INTRODUCTION: This phase I clinical trial was conducted to evaluate the safety of RP22 as a skin test reagent for tuberculosis (TB) diagnosis and to explore the appropriate dosage. METHODS: We used a randomized, double-blind, placebo-controlled identification allergen (IA) skin test. A total of 72 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lu, Liu, Xu-hui, Zhao, Zhang-yan, Li, Tao, Xi, Xiu-hong, Liu, Ping, Huang, Wei, Fan, Xiao-yong, Wu, Xue-qiong, Lu, Shui-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116472/
https://www.ncbi.nlm.nih.gov/pubmed/33829391
http://dx.doi.org/10.1007/s40121-021-00435-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116472/
https://www.ncbi.nlm.nih.gov/pubmed/33829391
http://dx.doi.org/10.1007/s40121-021-00435-5

Ejemplares similares